Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
Leukemia advance online publication, September 1 2017.
doi:10.1038/leu.2017.247
Authors: T P Hughes, B Leber, F Cervantes, N Spector, R Pasquini, N C D Clementino, A P Schwarer, P E Dorlhiac-Llacer, F-X Mahon, D Rea, A Guerci-Bresler, S Kamel-Reid, I Bendit, S Acharya, T Glynos, D Dalal, S Branford & J H Lipton
Source: Leukemia - Category: Hematology Authors: T P Hughes B Leber F Cervantes N Spector R Pasquini N C D Clementino A P Schwarer P E Dorlhiac-Llacer F-X Mahon D Rea A Guerci-Bresler S Kamel-Reid I Bendit S Acharya T Glynos D Dalal S Branford J H Lipton Source Type: research